Management of diabetes across the course of disease: minimizing obesity-associated complications

References

• National Diabetes Information Clearinghouse National Diabetes Statistics, 2011 2 2011 Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#allages Accessed July 28, 2011
   Google Scholar
• Geiss LS Pan L Cadwell B Gregg EW Benjamin SM Engelgau MM Changes in incidence of diabetes in US adults, 1997–2003 Am J Prev Med 2006 30 5 371 377 16627124
   PubMed Web of Science ®Google Scholar
• Khaodhiar L Cummings S Apovian CM Treating diabetes and prediabetes by focusing on obesity management Curr Diab Rep 2009 9 5 348 354 19793504
   PubMed Web of Science ®Google Scholar
• Bays HE Chapman RH Grandy S The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys Int J Clin Pract 2007 61 5 737 747 17493087
   PubMed Web of Science ®Google Scholar
• Nathan BM Moran A Metabolic complications of obesity in childhood and adolescence: more than just diabetes Curr Opin Endocrinol Diabetes Obes 2008 15 1 21 29 18185059
   PubMedGoogle Scholar
• Meigs JB Wilson PW Fox CS Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease J Clin Endocrinol Metab 2006 91 8 2906 2912 16735483
   PubMed Web of Science ®Google Scholar
• Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 4 229 234 9673301
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K Cederholm J Nilsson PM Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients Diabetologia 2009 52 1 65 73 18985314
   PubMed Web of Science ®Google Scholar
• Wei M Gaskill SP Haffner SM Stern MP Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study Diabetes Care 1998 21 7 1167 1172 9653614
   PubMed Web of Science ®Google Scholar
• La Vecchia C Giordano SH Hortobagyi GN Chabner B Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle Oncologist 2011 16 6 726 729 21632448
   PubMed Web of Science ®Google Scholar
• Larsson SC Permert J Hakansson N Naslund I Bergkvist L Wolk A Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts Br J Cancer 2005 93 11 1310 1315 16288300
   PubMed Web of Science ®Google Scholar
• Campbell RK Type 2 diabetes: where we are today. An overview of disease burden, current treatments, and treatment strategies J Am Pharm Assoc (2003) 2009 49 Suppl 1 S3 S9 19801365
   PubMed Web of Science ®Google Scholar
• Fisman EZ Tenenbaum A A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease Cardiovasc Diabetol 2009 8 38 50 19619327
   PubMed Web of Science ®Google Scholar
• Wilson PWF Kannel WB Silbershatz H D’Agostino RB Clustering of metabolic factors and coronary heart disease Arch Intern Med 1999 159 10 1104 1109 10335688
   PubMed Web of Science ®Google Scholar
• Dagenais GR Yi Q Mann JF Bosch J Pogue J Yusuf S Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease Am Heart J 2005 149 1 54 60 15660034
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X Blackburn G Brancati FL Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial Diabetes Care 2007 30 6 1374 1383 17363746
   PubMed Web of Science ®Google Scholar
• Shai I Schwarzfuchs D Henkin Y Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet N Engl J Med 2008 359 3 229 241 18635428
   PubMed Web of Science ®Google Scholar
• Wing RR Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial Arch Intern Med 2010 170 17 1566 1575 20876408
   PubMedGoogle Scholar
• Williamson DF Thompson TJ Thun M Flanders D Pamuk E Byers T Intentional weight loss and mortality among overweight individuals with diabetes Diabetes Care 2000 23 10 1499 1504 11023143
   PubMed Web of Science ®Google Scholar
• Stevens VJ Obarzanek E Cook NR Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II Ann Intern Med 2001 134 1 1 11 11187414
   PubMed Web of Science ®Google Scholar
• Eriksson KF Lindgarde F Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study Diabetologia 1991 34 12 891 898 1778354
   PubMed Web of Science ®Google Scholar
• Kosaka K Noda M Kuzuya T Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males Diabetes Res Clin Pract 2005 67 2 152 162 15649575
   PubMed Web of Science ®Google Scholar
• Hamman RF Wing RR Edelstein SL Effect of weight loss with lifestyle intervention on risk of diabetes Diabetes Care 2006 29 2 2102 2107 16936160
   PubMed Web of Science ®Google Scholar
• Orozco LJ Buchleitner AM Gimenez-Perez G Roque i Figuls M Richter B Mauricio D Exercise or exercise and diet for preventing type 2 diabetes mellitus Cochrane Database Syst Rev 2008 3 CD003054 18646086
   PubMed Web of Science ®Google Scholar
• Klein S Sheard NF Pi-Sunyer X Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Diabetes Care 2004 27 8 2067 2073 15277443
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes– 2011 Diabetes Care 2011 34 Suppl 1 S11 S61 21193625
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Albu JB Heilbronn LK Kelley DE Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes Diabetes 2010 59 3 627 633 20028945
   PubMed Web of Science ®Google Scholar
• Thomas D Elliott EJ Low glycaemic index, or low glycaemic load, diets for diabetes mellitus Cochrane Database Syst Rev 2009 1 CD006296 19160276
   PubMed Web of Science ®Google Scholar
• Westman EC Yancy WSJr Mavropoulos JC Marquart M McDuffie JR The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus Nutr Metab (Lond) 2008 5 36 19099589
   PubMed Web of Science ®Google Scholar
• Nuttall FQ Schweim K Hoover H Gannon MC Effect of the LoBAG30 diet on blood glucose control in people with type 2 diabetes Br J Nutr 2008 99 3 511 519 17868489
   PubMed Web of Science ®Google Scholar
• Jazet IM de Craen AJ van Schie EM Meinders AE Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes Diabetes Res Clin Pract 2007 77 1 70 76 17134786
   PubMed Web of Science ®Google Scholar
• Joslin Diabetes Center and Joslin Clinic Clinical Guideline for Pharmacological Management of Type 2 Diabetes January 9 2009 updated November, 2010. Available from: http://www.joslin.org/bin_from_cms/Pharma_guideline_11._10.pdf Accessed July 28, 2011
   Google Scholar
• Bolen S Feldman L Vassy J Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 2007 147 6 386 399 17638715
   PubMed Web of Science ®Google Scholar
• Schernthaner G Matthews DR Charbonnel B Hanefeld M Brunetti P Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial J Clin Endocrinol Metab 2004 89 12 6068 6076 15579760
   PubMed Web of Science ®Google Scholar
• Siraj ES Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? Cleve Clin J Med 2003 70 8 702 704 12959396
   PubMed Web of Science ®Google Scholar
• Virtanen KA Hallsten K Parkkola R Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects Diabetes 2003 52 2 283 290 12540598
   PubMed Web of Science ®Google Scholar
• Jorgensen CH Gislason GH Andersson C Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort study Cardiovasc Diabetol 2010 9 54 20843380
   PubMed Web of Science ®Google Scholar
• Brownstein JS Murphy SN Goldfine AB Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records Diabetes Care 2010 33 3 526 531 20009093
   PubMed Web of Science ®Google Scholar
• Chaudhry ZW Gannon MC Nuttall FQ Stability of body weight in type 2 diabetes Diabetes Care 2006 29 3 493 497 16505494
   PubMed Web of Science ®Google Scholar
• Moses R Slobodniuk R Boyages S Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 1999 22 1 119 124 10333912
   PubMed Web of Science ®Google Scholar
• Black C Donnelly P McIntyre L Royle PL Shepherd JP Thomas S Meglitinide analogues for type 2 diabetes mellitus Cochrane Database Syst Rev 2007 2 CD004654 17443551
   PubMed Web of Science ®Google Scholar
• van de Laar FA Lucassen PL Akkermans RP van de Lisdonk EH Rutten GE van Weel C Alpha-glucosidase inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2005 2 CD003639 15846673
   PubMed Web of Science ®Google Scholar
• Chiasson JL Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial Endocr Pract 2006 12 Suppl 1 25 30 16627376
   PubMedGoogle Scholar
• Hsieh SH Shih KC Chou CW Chu CH Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas Acta Diabetol 2011 48 1 71 77 20963449
   PubMed Web of Science ®Google Scholar
• Nemoto M Tajima N Kawamori R Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study Acta Diabetol 2011 48 1 15 20 20617348
   PubMed Web of Science ®Google Scholar
• Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Singh S Loke YK Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 2007 298 10 1189 1195 17848653
   PubMed Web of Science ®Google Scholar
• Wertz DA Chang CL Sarawate CA Willey VJ Cziraky MJ Bohn RL Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population Circ Cardiovasc Qual Outcomes 2010 3 5 538 545 20736441
   PubMed Web of Science ®Google Scholar
• Buyken AE von Eckardstein A Schulte H Cullen P Assmann G Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study Eur J Cardiovasc Prev Rehabil 2007 14 2 230 236 17446801
   PubMedGoogle Scholar
• Lecka-Czernik B Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis Curr Osteoporos Rep 2010 8 4 178 184 20809203
   PubMedGoogle Scholar
• Lewis JD Ferrara A Peng T Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 2011 34 4 916 922 21447663
   PubMed Web of Science ®Google Scholar
• Victoza^® (liraglutide [rDNA origin] injection), solution for subcutaneous use (prescribing information) Princeton, NJ Novo Nordisk Inc. 5 2011
   Google Scholar
• Fonseca VA Zinman B Nauck MA Goldfine AB Plutzky J Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies Am J Med 2010 123 7 S2 S10 20609666
   PubMed Web of Science ®Google Scholar
• Neumiller JJ Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors J Am Pharm Assoc (2003) 2009 49 Suppl 1 S16 S29 19801361
   PubMed Web of Science ®Google Scholar
• Monami M Marchionni N Mannucci E Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials Eur J Endocrinol 2009 160 6 909 917 19318378
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 2 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Jendle J Nauck MA Matthews DR Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Diabetes Obes Metab 2009 11 12 1163 1172 19930006
   PubMed Web of Science ®Google Scholar
• Pinkney J Fox T Ranganath L Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide Ther Clin Risk Manage 2010 6 401 411
   PubMed Web of Science ®Google Scholar
• Anderson SL Trujillo JM Association of pancreatitis with glucagon-like peptide-1 agonist use Ann Pharmacother 2010 44 904 909 20371755
   PubMed Web of Science ®Google Scholar
• Pratley RE Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes Medscape J Med 2008 10 7 171 18769687
   PubMedGoogle Scholar
• Richter B Bandeira-Echtler E Bergerhoff K Lerch CL Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2008 2 CD006739 18425967
   PubMedGoogle Scholar
• Frederich R Alexander JH Fiedorek FT A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes Postgrad Med 2010 122 3 16 27 20463410
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck M Bailey T Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 2010 375 9724 1447 1456 20417856
   PubMed Web of Science ®Google Scholar
• Younk LM Mikeladze M Davis SN Pramlintide and the treatment of diabetes: a review of the data since its introduction Expert Opin Pharmacother 2011 12 9 1439 1451 21564002
   PubMed Web of Science ®Google Scholar
• Singh-Franco D Perez A Harrington C The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis Diabetes Obes Metab 2011 13 2 169 180 21199269
   PubMed Web of Science ®Google Scholar
• Ryan GJ Jobe LJ Martin R Pramlintide in the treatment of type 1 and type 2 diabetes mellitus Clin Ther 2005 27 10 1500 1512 16330288
   PubMed Web of Science ®Google Scholar
• Chao EC A paradigm shift in diabetes therapy – dapagliflozin and other SGLT2 inhibitors Discov Med 2011 11 58 255 263 21447284
   PubMed Web of Science ®Google Scholar
• Strojek K Yoon K Hruba V Elze M Langkilde A Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Yadav M Nayyar I Mansfield TA List JF Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone [abstract] Diabetes 2011 60 Suppl 1 Abstract 0988-P
   Google Scholar
• Fiore K MedPage Today. ADA: Novel drug controls glucose, but may have cancer risk June 29 2011 Available from: http://www.medpagetoday.com/MeetingCoverage/ADA/27345 Accessed August 4, 2011
   Google Scholar
• Meece J Dispelling myths and removing barriers about insulin in type 2 diabetes Diabetes Educ 2006 32 1 Suppl 9S 18S 16439485
   PubMed Web of Science ®Google Scholar
• Hartman I Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence Clin Med Res 2008 6 2 54 67 18801953
   PubMedGoogle Scholar
• Groop L Widen E Franssila-Kallunki A Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 1989 32 8 599 605 2506091
   PubMed Web of Science ®Google Scholar
• Birkeland KI Hanssen KF Urdal P Berg K Vaaler S A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes J Intern Med 1994 236 3 305 313 8077888
   PubMed Web of Science ®Google Scholar
• Sinha A Formica C Tsalamandris C Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes Diabet Med 1996 13 1 40 46 8741811
   PubMed Web of Science ®Google Scholar
• Monami M Marchionni N Mannucci E Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis Diabetes Res Clin Pract 2008 81 2 184 189 18495286
   PubMed Web of Science ®Google Scholar
• Bazzano LA Lee LJ Shi L Reynolds K Jackson JA Fonseca V Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials Diabet Med 2008 25 8 924 932 18959605
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Derezinski T Martinez Ravn G Clauson P Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006 29 6 1269 1274 16732007
   PubMed Web of Science ®Google Scholar
• Fajardo Montanana C Hernandez Herrero C Rivas Fernandez M Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients – the PREDICTIVE™ BMI clinical trial Diabet Med 2008 25 8 916 923 18959604
   PubMed Web of Science ®Google Scholar
• Haak T Tiengo A Draeger E Suntum M Waldhausl W Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes Diabetes Obes Metab 2005 7 1 56 64 15642076
   PubMed Web of Science ®Google Scholar
• Raskin P Gylvin T Weng W Chaykin L Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 2009 25 6 542 548 19565569
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007 9 3 209 217 17391147
   PubMed Web of Science ®Google Scholar
• Hallschmid M Jauch-Chara K Korn O Euglycemic infusion of insulin detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects Diabetes 2010 59 4 1101 1107 20068139
   PubMed Web of Science ®Google Scholar
• Plank J Bodenlenz M Sinner F A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 2005 28 5 1107 1112 15855574
   PubMed Web of Science ®Google Scholar
• Tone A Iseda I Higuchi C Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes Exp Clin Endocrinol Diabetes 2010 118 5 320 324 20072962
   PubMed Web of Science ®Google Scholar
• Apovian CM Gokce N Clinician update: obesity and cardiovascular disease Circulation 2011
   Google Scholar
• Weight Control Information Network; National Institute of Diabetes and Digestive and Kidney Diseases Prescription medications for the treatment of obesity 11 2004 updated Dec, 2010. Available from: http://win.niddk.nih.gov/Publications/prescription.htm Accessed July 28, 2011
   Google Scholar
• Li Z Maglione M Tu W Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 2005 142 7 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Hutton B Fergusson D Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials Am J Clin Nutr 2004 80 6 1461 1468 15585756
   PubMed Web of Science ®Google Scholar
• Torgerson JS Hauptman J Boldrin MN Sjostrom L XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 2004 27 1 155 161 14693982
   PubMed Web of Science ®Google Scholar
• Kopelman P Groot Gde H Rissanen A Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical) Obesity (Silver Spring) 2010 18 1 108 115 19461584
   PubMed Web of Science ®Google Scholar
• Le Riche WH Van Belle G Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects Can Med Assoc J 1962 87 29 31 14463177
   PubMed Web of Science ®Google Scholar
• Fletcher PC Napolitano A Skeggs A Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum J Neurosci 2010 30 43 14346 14355 20980590
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Abbott Laboratories agrees to withdraw its obesity drug Meridia [press release] October 8 2010 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm228812.htm Accessed July 28, 2011
   Google Scholar
• James WP Caterson ID Coutinho W Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N Engl J Med 2010 363 10 905 917 20818901
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M Ashton J Herbison P Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study Drug Saf 2010 33 7 605 613 20553061
   PubMed Web of Science ®Google Scholar
• Bello NT Liang NC The use of serotonergic drugs to treat obesity – is there any hope? Drug Des Devel Ther 2011 5 95 109
   PubMed Web of Science ®Google Scholar
• Smith SR Weissman NJ Anderson CM Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 2010 363 3 245 256 20647200
   PubMed Web of Science ®Google Scholar
• Astrup A Madsbad S Breum L Jensen TJ Kroustrup JP Larsen TM Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial Lancet 2008 372 9653 1906 1913 18950853
   PubMed Web of Science ®Google Scholar
• Fraende M Reuters. Neurosearch seeking partner for obesity drug [press release] May 26 2011 Available from: http://www.reuters.com/article/2011/05/26/neurosearch-idUSLDE74212620110526 Accessed July 28, 2011
   Google Scholar
• Shionogi and Co, Ltd Research and development at Shionogi March 10 2011 Available from: http://www.shionogi.co.jp/ir_en/explanatory/pdf/e_p110310.pdf Accessed July 28, 2011
   Google Scholar
• Yukioka H A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent Nippon Yakurigaku Zasshi 2010 136 5 270 274 Japanese 21079365
   PubMedGoogle Scholar
• Klonoff DC Greenway F Drugs in the pipeline for the obesity market J Diabetes Sci Technol 2008 2 5 913 918 19885278
   PubMedGoogle Scholar
• Wadden TA Foreyt JP Foster GD Weight loss with naltrexone SR/Bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial Obesity (Silver Spring) 2011 19 1 110 120 20559296
   PubMed Web of Science ®Google Scholar
• Wood S Heartwire. FDA declines approval for Contrave diet drug; asks for CVD outcomes studies [press release] February 1 2011 Available from: http://www.medscape.com/viewarticle/736616 Accessed July 28, 2011
   Google Scholar
• Ioannides-Demos LL Piccenna L McNeil JJ Pharmacotherapies for obesity: past, current, and future therapies J Obes 2011 2011 179674 21197148
   PubMedGoogle Scholar
• Bays H Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease Expert Rev Cardiovasc Ther 2010 8 12 1777 1801 20707765
   PubMedGoogle Scholar
• Miller R Heartwire. FDA rejects Qnexa, asks for more info [press release] October 29 2010 Available from: http://www.medscape.com/viewarticle/731653 Accessed July 28, 2011
   Google Scholar
• Hunt S Russell A Smithson WH Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register Neurology 2008 71 4 272 276 18645165
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration FDA Drug Safety Communication: risk of oral clefts in children born to mothers taking Topamax (topiramate) March 4 2011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm Accessed July 28, 2011
   Google Scholar
• Ravussin E Smith SR Mitchell JA Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity (Silver Spring) 2009 17 9 1736 1743 19521351
   PubMed Web of Science ®Google Scholar
• Astrup A Rossner S van Gaal L Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 2009 374 9701 1606 1616 19853906
   PubMed Web of Science ®Google Scholar
• Weight Control Information Network and National Institute of Diabetes and Digestive and Kidney Diseases Bariatric surgery for severe obesity. [Page on the Internet.] 3 2009 Available from: http://win.niddk.nih.gov/publications/gastric.htm#whataresurg Accessed July 28, 2011
   Google Scholar
• Ferchak CV Meneghini LF Obesity, bariatric surgery and type 2 diabetes – a systematic review Diabetes Metab Res Rev 2004 20 6 438 445 15386803
   PubMed Web of Science ®Google Scholar
• Buchwald H Avidor Y Braunwald E Bariatric surgery: a systematic review and meta-analysis JAMA 2004 292 14 1724 1737 15479938
   PubMed Web of Science ®Google Scholar
• Rubino F Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis Diabetes Care 2008 31 Suppl 2 S290 S296 18227499
   PubMed Web of Science ®Google Scholar
• Rubino F Kaplan LM Schauer PR Cummings DE The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus Ann Surg 2010 251 3 399 405 19934752
   PubMed Web of Science ®Google Scholar
• Rodriguez-Grunert L Galvao Neto MP Alamo M Ramos AC Baez PB Tarnoff M First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve Surg Obes Relat Dis 2008 4 1 55 59 18201671
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Gastroenterology and Urology Devices Panel Meeting December 3 2010 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/Gastroenterology-UrologyDevicesPanel/UCM236137.pdf Accessed July 28, 2011
   Google Scholar
• Ponce J Haynes B Paynter S Effect of lap-band-induced weight loss on type 2 diabetes mellitus and hypertension Obes Surg 2004 14 10 1335 1342 15603648
   PubMed Web of Science ®Google Scholar
• Sjostrom L Narbro K Sjostrom CD Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 2007 357 8 741 752 17715408
   PubMed Web of Science ®Google Scholar
• Pournaras DJ Osborne A Hawkins SC Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes Ann Surg 2010 252 6 966 971 21107106
   PubMed Web of Science ®Google Scholar
• Kashyap SR Daud S Kelly KR Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes Int J Obes (Lond) 2010 34 3 462 471 20029383
   PubMed Web of Science ®Google Scholar
• Thaler JP Cummings DE Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery Endocrinology 2009 150 6 2518 2525 19372197
   PubMed Web of Science ®Google Scholar
• Rubino F Moo TA Rosen DJ Dakin GF Pomp A Diabetes surgery: a new approach to an old disease Diabetes Care 2009 32 Suppl 2 S368 S372 19875583
   PubMed Web of Science ®Google Scholar
• le Roux CW Aylwin SJ Batterham RL Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters Ann Surg 2006 243 1 108 114 16371744
   PubMed Web of Science ®Google Scholar
• Bose M Machineni S Olivan B Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding Obesity (Silver Spring) 2010 18 6 1085 1091 20057364
   PubMed Web of Science ®Google Scholar
• Laferrere B Swerdlow N Bawa B Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes J Clin Endocrinol Metab 2010 95 8 4072 4076 20501690
   PubMed Web of Science ®Google Scholar
• Moore TJ Alsabeeh N Apovian CM Weight, blood pressure, and dietary benefits after 12 months of a Web-based Nutrition Education Program (DASH for health): longitudinal observational study J Med Internet Res 2008 10 4 e52 19073541
   PubMed Web of Science ®Google Scholar
• Lee WC Conner C Hammer M Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Curr Med Res Opin 2011 27 5 897 906 21348806
   PubMed Web of Science ®Google Scholar
• Minshall ME Oglesby AK Wintle ME Valentine WJ Roze S Palmer AJ Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus Value Health 2008 11 1 22 33 18237357
   PubMed Web of Science ®Google Scholar
• Tunis SL Minshall ME Conner C Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis Curr Med Res Opin 2009 25 5 1273 1284 19366302
   PubMed Web of Science ®Google Scholar
• Picot J Jones J Colquitt JL The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation [review] Health Technol Assess 2009 13 41 iii iv 1 190
   Web of Science ®Google Scholar